Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth Getz

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Nature Reviews. Drug Discovery|July 21, 2018
Trends driving clinical trials into large clinical care settingsKenneth Getz
Pharmaceutical Medicine|January 15, 2020
Reflections on the Evolution of Patient Engagement in Drug DevelopmentKenneth Getz
International Journal of Environmental Research and Public Health|May 15, 2014
Improving protocol design feasibility to drive drug development economics and performanceKenneth Getz
Therapeutic Innovation & Regulatory Science|May 11, 2024
Examining the Association Between DCT Solutions Use and Participant Diversity in Clinical TrialsZachary Smith, Kenneth Getz
Drug Safety|June 26, 2015
Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting PracticesStella Stergiopoulos, Kenneth Getz
American Journal of Therapeutics|January 29, 2008
Racial disparities among clinical research investigatorsKenneth Getz, Laura Faden
Expert Review of Clinical Pharmacology|October 30, 2013
Drug development study designs have reached the danger zoneKenneth Getz, Rafael Campo
Therapeutic Innovation & Regulatory Science|December 1, 2023
A Case Study Assessment on the Rationale for, and Relevance of, Non-Core Protocol DataZachary Smith, Kenneth Getz
Therapeutic Innovation & Regulatory Science|June 10, 2022
Quantifying Diversity and Representation in Pivotal Trials Leading to Marketing Authorization in EuropeZachary Smith, Emily Botto, Kenneth Getz
Therapeutic Innovation & Regulatory Science|August 12, 2022
Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease SubgroupsKenneth Getz, Zachary Smith, Marcy Kravet
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Nature Reviews. Drug Discovery|July 21, 2018
Trends driving clinical trials into large clinical care settingsKenneth Getz
Pharmaceutical Medicine|January 15, 2020
Reflections on the Evolution of Patient Engagement in Drug DevelopmentKenneth Getz
International Journal of Environmental Research and Public Health|May 15, 2014
Improving protocol design feasibility to drive drug development economics and performanceKenneth Getz
Therapeutic Innovation & Regulatory Science|May 11, 2024
Examining the Association Between DCT Solutions Use and Participant Diversity in Clinical TrialsZachary Smith, Kenneth Getz
Drug Safety|June 26, 2015
Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting PracticesStella Stergiopoulos, Kenneth Getz
American Journal of Therapeutics|January 29, 2008
Racial disparities among clinical research investigatorsKenneth Getz, Laura Faden
Expert Review of Clinical Pharmacology|October 30, 2013
Drug development study designs have reached the danger zoneKenneth Getz, Rafael Campo
Therapeutic Innovation & Regulatory Science|December 1, 2023
A Case Study Assessment on the Rationale for, and Relevance of, Non-Core Protocol DataZachary Smith, Kenneth Getz
Therapeutic Innovation & Regulatory Science|June 10, 2022
Quantifying Diversity and Representation in Pivotal Trials Leading to Marketing Authorization in EuropeZachary Smith, Emily Botto, Kenneth Getz
Therapeutic Innovation & Regulatory Science|August 12, 2022
Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease SubgroupsKenneth Getz, Zachary Smith, Marcy Kravet
Pageof 6